E-therapeutics Share Discussion Threads

[meijiman] 06/4/2020 12:13

Question is ...is it still worth buying? I've done some research but find it hard to get a firm grip on its prospects. Late stage discussions does sound intriguing!

[dplewis1] 06/4/2020 11:55

Wow just keeps grinding higher. Regretting slicing in the mid 7's now..

[the stigologist] 06/4/2020 10:29

News and this hits 40p in a flash now

[the stigologist] 05/4/2020 23:18

Mortazavi is so on the ball

The Government opinion seems to be we don't have time to develop new drugs to treat Coronavirus

The best approach is to repurpose existing drugs

Trump et al are desperate to push Hydroxychloroquine based on spurious and specious anecdotal 'evidence'

What is needed is serious in-silico / Computational Biology / AI / ML crunching of any and all data relating to hydroxychloroquine studies and Coronavirus and any other drugs to see what are the right combinations/sequencing/dosing etc of drugs

This would seem to be the ideal time for Companies like ETX to step up to the plate and offer their services. They can do the computer hard yards and thus mitigate and expedite a lot of that work.

So we may see news on that front.

Added to that we have the 'late stage discussions' for EXCITING collaborations which could be Revenue-Generating or Value-Creating !!!

[harvey26311] 05/4/2020 22:17

Hopefully we will see an interesting week ahead

[the stigologist] 04/4/2020 10:07

Interesting

[the stigologist] 03/4/2020 19:31

Great end of week close and candle

Going into Spring wouldn't it be a great statement of intent and British Big Pharma intent to be at forefront of the field to announce some tie ups in the exciting AI/ML area ?

Hint hint AZN and GSK

[dplewis1] 03/4/2020 17:31

Keeping me nicely placed in the top 10 of stockpedia challenge as well!

[the stigologist] 03/4/2020 16:59

This is melting up with no news.

Maybe wait until it's 20p before releasing news

[the stigologist] 03/4/2020 14:14

ETX Mkt Cap c.£30m

No brainer when you consider

Comparitors

Google Deepmind $10 Billion? (Google bought Deepmind for $500m in 2014)
Exscientia $1 Billion+
BenevolentAI $1 Billion+

and it is clear from ETX Investor Presentation they are in 'late stage discussions' with likes of Glaxo and Astra Zeneca

In current environment lots of money will be thrown at Bios/Pharmas by Governments/Corporates etc

In current environment one of only ways Bios/Pharmas can continue operating is working from home and doing 'in silico' work (perfect for likes of PYC, C4XD, ETX )

Just imagine if they announced tie up with GSK or AZN !

[dplewis1] 03/4/2020 13:38

Back to 2017 levels now (not that I owned them then) but this is ticking up nicely.

[matt123d] 02/4/2020 21:53

Late reported 335k and 228k trades responsible for the rise. Supply coming from somewhere unless market makers are now short.

[the stigologist] 02/4/2020 16:35

"late stage discussions"
on a NUMBER (multiple)
of
revenue-generating
and
value-creating
deals

[dplewis1] 02/4/2020 16:17

Its pretty impressive stuff considering there have been no new deals announced .. imagine if they get a juicy revenue generating collaboration..

[matt123d] 02/4/2020 16:09

Someone's on the bid for these. Should see the 12-15p range short term.

[the stigologist] 02/4/2020 16:00

Whoosh...
Breakout coming
This will be new 52 week closing high

[the stigologist] 02/4/2020 13:06

Oxford-based drug discovery firm e-therapeutics has hired Dr Laura Roca-Alonso as its Chief Business Office.

Roca-Alonso brings strategic expertise in advanced therapeutics and platform technologies, encompassing corporate and business development, portfolio strategy, business planning, competitive intelligence and communications.

From 2014 until 2019, she held positions at Silence Therapeutics, a publicly listed firm, culminating in her role as VP, Head of Corporate Development.

Most recently, Roca-Alonso served as Director of Business Development at Gyroscope Therapeutics, a clinical-stage retinal gene therapy company.

She received her Ph.D. from Imperial College London, an MRes Biomedicine from University College London and her BSc (hons) in Biotechnology from Universitat Autonoma de Barcelona.

The AIM-listed firm uses a computer-based approach to drug discovery, founded on its expertise in network biology. It has created two proprietary productive technologies.

The first is Network-driven Drug Discovery ("NDD"), which is based on network science, statistics, machine learning and artificial intelligence.

The second is Genome Associated Interaction Networks ("GAINs"). GAINs is a novel approach to functional genomics, based on the same validated network biology and analytics expertise that underpins our NDD technologies.

“e-therapeutics has built an impressive network biology-based discovery capability that is being leveraged to gain actionable insights into complex disease and to enable early-stage drug discovery in areas of high unmet need. I am excited to be joining the team at this important time for the company to help maximise the value of its unique platform technologies,” said Dr Roca-Alonso.

Ali Mortazavi, Executive Chairman of the firm added: "We are delighted to welcome Laura to the team at e-therapeutics. Her broad experience will be a great asset as we continue to build the company."

[the stigologist] 02/4/2020 10:50

Excellent. Bringing in someone he already knows to deliver on Business Development side.

[dplewis1] 02/4/2020 07:04

Seems like a decent appointment here..one of his old SLN bods. "important time for the company to help maximise the value of its unique platform technologies"

[the stigologist] 02/4/2020 00:45

It's a weekly chart.

200 weeks is about 4 years

[dplewis1] 01/4/2020 22:52

200 day moving average?

[the stigologist] 01/4/2020 22:12

First time above the 200 week moving average since 2015 collapse

[the stigologist] 01/4/2020 17:37

2 years cash runway